AWM
VRTX icon

Avior Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Avior Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Sell
3,045
-9
-0.3% -$3.99K 0.04% 290
2026
Q1 		$1.36M Sell
3,054
-248
-8% -$116K 0.04% 296
2025
Q4 		$1.5M Buy
3,302
+164
+5% +$70.7K 0.05% 240
2025
Q3 		$1.23M Buy
3,138
+188
+6% +$78.6K 0.04% 269
2025
Q2 		$1.31M Buy
2,950
+648
+28% +$299K 0.05% 239
2025
Q1 		$1.12M Sell
2,302
-667
-22% -$311K 0.04% 246
2024
Q4 		$1.2M Buy
2,969
+436
+17% +$202K 0.04% 251
2024
Q3 		$1.18M Buy
2,533
+113
+5% +$54.3K 0.05% 257
2024
Q2 		$1.13M Sell
2,420
-686
-22% -$298K 0.05% 244
2024
Q1 		$1.3M Buy
3,106
+384
+14% +$162K 0.06% 234
2023
Q4 		$1.11M Buy
2,722
+48
+2% +$17.7K 0.07% 193
2023
Q3 		$930K Hold
2,674
– – 0.06% 207
2023
Q2 		$941K Hold
2,674
– – 0.06% 208
2023
Q1 		$842K Sell
2,674
-251
-9% -$75.3K 0.06% 224
2022
Q4 		$845K Sell
2,925
-112
-4% -$34.1K 0.06% 210
2022
Q3 		$878K Sell
3,037
-119
-4% -$34.2K 0.07% 183
2022
Q2 		$889K Sell
3,156
-964
-23% -$258K 0.09% 160
2022
Q1 		$1.07M Sell
4,120
-630
-13% -$150K 0.09% 155
2021
Q4 		$1.04M Hold
4,750
– – 0.09% 191
2021
Q3 		$861K Buy
4,750
+2,430
+105% +$474K 0.07% 209
2021
Q2 		$467K Buy
2,320
+1,347
+138% +$282K 0.05% 314
2021
Q1 		$209K Hold
973
– – 0.02% 397
2020
Q4 		$229K Buy
973
+246
+34% +$56.4K 0.03% 369
2020
Q3 		$197K Sell
727
-173
-19% -$47.7K 0.03% 378
2020
Q2 		$261K Sell
900
-389
-30% -$105K 0.04% 350
2020
Q1 		$306K Sell
1,289
-26
-2% -$5.96K 0.06% 267
2019
Q4 		$287K Buy
1,315
+26
+2% +$5.26K 0.05% 330
2019
Q3 		$218K Buy
1,289
+5
+0.4% +$885 0.04% 353
2019
Q2 		$235K Buy
+1,284
New +$224K 0.04% 338
2018
Q2 		– Sell
-9
Closed -$1K – 859
2018
Q1 		$1K Hold
9
– – ﹤0.01% 766
2017
Q4 		$1K Buy
+9
New +$1.33K ﹤0.01% 770

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Avior Wealth Management's VRTX Position: Q2 2026 in Review

Avior Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.29% in Q2 2026, selling an estimated $3.99K and leaving 3,045 shares worth $1.51M. The position accounts for 0.04% of the portfolio, ranked #290.

Avior Wealth Management first reported a position in VRTX in Q4 2017 and has held it in 31 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Avior Wealth Management held 3,045 shares of Vertex Pharmaceuticals worth $1.51M as of Q2 2026.
  • Avior Wealth Management sold 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
  • Vertex Pharmaceuticals made up 0.04% of Avior Wealth Management's portfolio in Q2 2026, its #290 holding.
  • Avior Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 31 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Avior Wealth Management's 13F filing for Q2 2026, filed 7 Jul 2026.